A detailed history of Goldman Sachs Group Inc transactions in Harrow Health, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 152,992 shares of HROW stock, worth $5.97 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
152,992
Previous 80,269 90.6%
Holding current value
$5.97 Million
Previous $1.68 Million 310.38%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$20.85 - $46.47 $1.52 Million - $3.38 Million
72,723 Added 90.6%
152,992 $6.88 Million
Q2 2024

Aug 13, 2024

BUY
$10.0 - $21.64 $316,470 - $684,841
31,647 Added 65.09%
80,269 $1.68 Million
Q1 2024

May 15, 2024

SELL
$9.3 - $13.23 $52,070 - $74,074
-5,599 Reduced 10.33%
48,622 $643,000
Q4 2023

Feb 13, 2024

BUY
$8.1 - $16.36 $112,800 - $227,829
13,926 Added 34.56%
54,221 $607,000
Q3 2023

May 14, 2024

SELL
$14.03 - $22.08 $195,381 - $307,486
-13,926 Reduced 25.68%
40,295 $579,000
Q3 2023

Nov 14, 2023

SELL
$14.03 - $22.08 $915,710 - $1.44 Million
-65,268 Reduced 61.83%
40,295 $579,000
Q2 2023

May 14, 2024

BUY
$17.37 - $28.08 $525,511 - $849,532
30,254 Added 40.17%
105,563 $2.01 Million
Q2 2023

Aug 14, 2023

BUY
$17.37 - $28.08 $525,511 - $849,532
30,254 Added 40.17%
105,563 $2.01 Million
Q1 2023

May 14, 2024

BUY
$13.84 - $21.46 $291,857 - $452,548
21,088 Added 38.89%
75,309 $1.59 Million
Q1 2023

May 11, 2023

BUY
$13.84 - $21.46 $1.04 Million - $1.62 Million
75,309 New
75,309 $1.59 Million
Q2 2022

Aug 15, 2022

SELL
$5.75 - $7.74 $58,310 - $78,491
-10,141 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$6.77 - $8.66 $13,187 - $16,869
-1,948 Reduced 16.11%
10,141 $69,000
Q4 2021

Feb 14, 2022

BUY
$8.5 - $12.0 $102,756 - $145,068
12,089 New
12,089 $104,000

Others Institutions Holding HROW

About HARROW HEALTH, INC.


  • Ticker HROW
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 27,070,000
  • Market Cap $1.06B
  • Description
  • Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...
More about HROW
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.